DOCSLIB.ORG

Advances in BIOPHARMACEUTICAL TECHNOLOGY in CHINA New Second Edition!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in BIOPHARMACEUTICAL TECHNOLOGY in CHINA New Second Edition! Establish China partnerships Create Effective Strategies to EXPAND YOUR GLOBAL REACH! Advances in BIOPHARMACEUTICAL TECHNOLOGY in CHINA New Second Edition! A great opportunity exists in working with Chinese companies to establish scientific and business partnerships, and to create effective strategies. However, success in Asia in the new millennium will require changes in partnerships between Western and Asian companies. Every company faces the question “What should our China strategy be?” This volume, a co-publication of the Society for Industrial BY THE NUMBERS Microbiology and Biotechnology and BioPlan Associates, Inc., provides an overview of the biopharmaceutical industry, ● 102 Internationally and the state of technology in China. Recognized Authors ● 21 Peer-Reviewers Readers will be able to: ● 1,139 Pages 1. Assess the state of biopharmaceutical development in China ● 70 Translated Chapters 2. Understand general business practices ● 5 Case Studies and China Briefs 3. Analyze business opportunities and identify potential partners ● 200+ Tables and Figures A peer-reviewed, ready reference for all aspects of ● 300+ References biopharmaceuticals in China, including an understanding of the ● Over 2,000 Index Entries China biopharma current situation, and future opportunities. Readers receive a comprehensive assessment of the state-of-the- This authoritative, peer-reviewed study industry, trends, and analysis. Information on all types of organizations is produced in collaboration with the involved in biopharma in China, whether they are domestic, Society for Industrial Microbiology and Biotechnology. multinational, or government. FOR MORE INFORMATION: : Download Table of Contents or visit Order Online Now ▶ http://bioplanassociates.com/china ISBN: 9781934106341 2275 Research Blvd, Suite 500, Rockville, MD 20850 | www.bioplanassociates.com | E-mail: [email protected] or call +1–301–921–5979 Chapter Preview PREFACE - Study Overview SECTION 6: Vaccine Industry in China SECTION 1: Introduction to Advances in China SECTION 7: Biopharma Contract Services and Clinical Biopharmaceuticals Trials in China SECTION 2: Innovation in China Biopharmaceuticals: SECTION 8: Doing Business in China: Investment and Historical and Current Climate Intellectual Property SECTION 3: Biopharmaceuticals and Healthcare SECTION 9: Future of China’s Biopharma Industry Systems and Structure in China Appendices SECTION 4: Biopharmaceutical Manufacturing in China: Appendix A: Directory of Biologics on Market & Clinical Operational and Quality Trends Development in China SECTION 5: Advances in Biological Development Appendix B: Directory: Top 60 Biopharmaceutical in China Manufacturers in China Author Organizations Amgen Asia Research and Development Center Genor BioPharma SDIC Fund Anhui Anke Biotechnology (Group) Co., Ltd. Guangzhou Nanotides Pharmaceuticals, Co. Ltd. Shanghai Institutes for Biological Sciences AstraZeneca/MedImmune Hengrui Pharma Shenzhen Polytechnic University AutekBio Hua Medicine Shenzhen Research Institute of Nanjing University BeiGene (Suzhou) Co., Ltd. Huaota Biopharma Sichuan University Beijing Minhai Biotechnology Co., Ltd. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. Sinolink Securities Institute Beijing University Innova Med Biotechnology Co., Ltd. Suzhou Sirnaomics Pharmaceuticals, Co. Ltd. Betta Pharma Co., Ltd. Innovent Biologics Tasly Sants Pharmaceutical Boehringer Ingelheim China Jiangsu TargetPharma Laboratories Inc. Tianjin International Joint Academy of Biomedicine CanSino Biologics Inc. Jiayu (Suzhou) Biomedical Incorporated Tot Biopharm Co., Ltd. Celgene Pharma Jilin University VenturePharma Cellyan Therapeutics (Wuhan) Co., Ltd. L.E.K. Consulting Walter Biotech Consultancy Changzhou High-Tech Res. Inst. of Nanjing University Macau University of Science and Technology Wuhan YZY Biopharma Co., Ltd. China Nat’l Ctr. for Biotechnology Dev. (CNCBD) Nanjing University WuXi Biologics China Technology Exchange Peking University Xiamen Wantai Canghai Chinese Academy of Sciences Perkins Coie, LLP XingYe Securities Chinese Pharmacopoeia Commission PersonGen Yusen Capital Complya Asia Co., Ltd. Pharmcodia Zai Lab. CStone Pharmaceuticals Pullan Consulting Zensun (Shanghai) Sci & Tech Co., Ltd. Dacheng LLP Qiming Venture Partners Zhejiang Hisun Pharmaceutical Co., Ltd. Doer Bio Quacell Biotechnology Company Ltd. Zhejiang Terui Fudan University Renmin University Learn more about China Partnerships in Biopharma FOR MORE INFORMATION: Order Online Now ▶ Download Table of Contents or visit http://bioplanassociates.com/china ISBN: 9781934106341 2275 Research Blvd, Suite 500, Rockville, MD 20850 | www.bioplanassociates.com | E-mail: [email protected] or call +1–301–921–5979.
Load more

Recommended publications
  • Biopharmaceutical Sector Update: Market Outlook for 2021
    Biopharmaceutical Sector Update Market Outlook for 2021 January 11, 2021 © 2021. All rights reserved. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. Table of Contents An Extraordinary Year: Top 10 Biopharma Events of 2020 4 Biopharma Sector Outlook for 2021 20 The Evolving World of Biotech Company Formation 26 Implications of the U.S. Election on the Biopharma Sector 31 Update on Covid-19, Capital Markets and M&A Activity 39 About Torreya 50 Key Topics in This Update In this report we discuss three topics that are front of mind in our industry: We have lived through an Given the exceptional performance of the biopharma extraordinary year for the #1 market in 2020, what does 2021 hold? biopharmaceutical industry. Given excellent protection data on two COVID-19 vaccines we now appear It appears likely that with widespread vaccination, #2 the COVID-19 pandemic will recede in 2021. What to be at the beginning of the end of does this imply for the biopharma sector? the COVID-19 pandemic. A “return to normalcy” appears possible in 2021 despite a very challenging situation What are the implications of the U.S. political #3 situation for the global biopharmaceutical sector? at present with the pandemic. 3 An Extraordinary Year: Top 10 Biopharma Events of 2020 4 Event #1 COVID-19 Vaccines Portend a New Normal The FDA has approved two COVID-19 vaccines as of Jan 2021 and more vaccine approvals are likely.
    [Show full text]
  • The Future for Biosensors in Biopharmaceutical Production
    Pharmaceutical Commentary BRACEWELL & POLIZZI The future for biosensors in biopharmaceutical production 2 Commentary The future for biosensors in biopharmaceutical production Pharm. Bioprocess. Keywords: bioprocess monitoring • bioprocess control • in-vivo biosensor • PAT Daniel G Bracewell*,1 • synthetic biology & Karen M Polizzi2 1The Advanced Centre for Biochemical Engineering, Department of Biochemical A defining feature of bioprocesses is the need straightforward. This is not to say there have Engineering, University College London, for measurement, monitoring and control; in not been significant successes: Torrington Place, London, WC1E 7JE, UK the context of biopharmaceuticals this need 2Department of Life Sciences & Centre • The world’s diabetic population depends is further heightened by the absolute require- for Synthetic Biology & Innovation, on blood glucose measurements to admin- Imperial College London, London, UK ment to ensure the quality of the product [1] . ister insulin based on an amperometric *Author for correspondence: This is evidenced by the size of bioanalytical based biosensor technology (enzyme elec- [email protected] endeavor found within the R&D programs trodes). This represents the largest single of the major biopharmaceutical companies biosensor application in terms of numbers and the supplier industry that caters for this of devices and market size; instrumentation need. It is a need that grows at a pace reflected in the initiatives involv- • Optical biosensors, largely surface plas- ing the regulatory authorities such as PAT mon resonance (BIAcore) has become central to the larger vision of QbD. At the the default method to directly mea- core of these attempts to improve biophar- sure protein–protein interactions in the maceutical production is the need for rapid, laboratory.
    [Show full text]
  • Biopharmaceutical Notes
    An Overview of the BioPharmaceutical Products and Market By Paul DiMarco, Vice President, Global Commercial Program, BioSpectra Inc. Table of Contents INTRODUCTION: ........................................................................................................................................ 2 History ....................................................................................................................................................... 2 Background information ........................................................................................................................... 3 Defining biological products ..................................................................................................................... 4 Small vs. Large Molecule Regulation and Registration in the USA and EU ............................................... 6 Controversial Regulatory Concepts: ......................................................................................................... 7 Extrapolation: ........................................................................................................................................ 7 Switching: .............................................................................................................................................. 8 Interchangeability: ................................................................................................................................ 9 Harmonization: ....................................................................................................................................
    [Show full text]
  • How Scientist/Founders Lead Successful Biopharmaceutical
    Antioch University AURA - Antioch University Repository and Archive Student & Alumni Scholarship, including Dissertations & Theses Dissertations & Theses 2008 How Scientist/Founders Lead Successful Biopharmaceutical Organizations: A Study of Three Companies Lynn Johnson Langer Antioch University - PhD Program in Leadership and Change Follow this and additional works at: http://aura.antioch.edu/etds Part of the Business Administration, Management, and Operations Commons, Medicine and Health Sciences Commons, and the Organizational Behavior and Theory Commons Recommended Citation Langer, Lynn Johnson, "How Scientist/Founders Lead Successful Biopharmaceutical Organizations: A Study of Three Companies" (2008). Dissertations & Theses. 138. http://aura.antioch.edu/etds/138 This Dissertation is brought to you for free and open access by the Student & Alumni Scholarship, including Dissertations & Theses at AURA - Antioch University Repository and Archive. It has been accepted for inclusion in Dissertations & Theses by an authorized administrator of AURA - Antioch University Repository and Archive. For more information, please contact [email protected], [email protected]. HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES Lynn Johnson Langer A DISSERTATION Submitted to the Ph.D. in Leadership & Change Program of Antioch University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May, 2008 This is to certify that the dissertation entitled: HOW SCIENTIST/FOUNDERS
    [Show full text]
  • The Economic Impact of the US Biopharmaceutical
    THE ECONOMIC IMPACT OF THE U.S. BIOPHARMACEUTICAL INDUSTRY: 2017 National and State Estimates DECEMBER 2019 TEConomy Partners, LLC is a global leader in research, analysis, and strategy for innovation-driven economic development. Today we’re helping nations, states, regions, universities, and industries blueprint their future and translate knowledge into prosperity. The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative pharmaceutical research and biotechnology companies, which are devoted to developing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new treatments and cures. TEConomy Partners, LLC (TEConomy) endeavors at all times to produce work of the highest quality, consistent with our contract commitments. However, because of the research and/or experimental nature of this work, the client undertakes the sole responsibility for the consequence of any use or misuse of, or inability to use, any information or result obtained from TEConomy, and TEConomy, its partners, or employees have no legal liability for the accuracy, adequacy, or efficacy thereof. TABLE OF CONTENTS Executive Summary ......................................................................................................1 Introduction: An Industry Defined by Innovation .................................................... 3 The Broad Scope and Scale of the Biopharmaceutical Industry ............................5 Defining the
    [Show full text]
  • Biopharmaceutical Release Testing
    Biopharmaceutical Release Testing To support your commercial product and clinical trial material release testing needs, Eurofins BioPharma Product Testing offers the capacity and breadth of capabilities to test your formulated bulk, final product or in-process materials in a timely manner. We test materials against specifications for identity, purity, potency, impurities, physical properties and safety under strict cGMP compliance, and we customize individual programs to streamline lab documentation and reporting for the most efficient and quality-focused data deliverable possible. Our multi-shift laboratory operations are designed to provide extensive capacity for larger volume release programs, as well as flexibility for smaller programs in a manner that allows for aggressive cycle times. Our release testing services are backed by an outstanding scientific approach to problem solving and extensive expertise in Method Development and Validation. Why Choose Eurofins BioPharma Product Testing? • We have in-depth experience working with every Potency/Bioassay Services type of modality and have the flexibility and extensive • Development and validation of cell-based bioassays instrument capacity within our team to meet the using multiple formats, including absorbance, ever-changing demands of production schedules fluorescence, time-resolved fluorescence and and timelines. luminescence as well as binding and competitive ELISAs. • We are a center of excellence for development, optimization, and transfer of in vitro bioassays for • Assay optimization to eliminate sources of variability potency. and ensure consistent performance for QC release. • Our breadth of capabilities allows us to perform • Multiple software packages available for data all testing of even the most complex conjugated analysis, including Softmax Pro and StatLIA.
    [Show full text]
  • 2019 FDA Biopharmaceutical Approvals: a Record Year for Follow-On Products, but Is Innovation Lagging? Bioplan Associates, Inc
    Confidential White Paper – Not for Distribution 2019 FDA Biopharmaceutical Approvals: A Record Year for Follow-on Products, But is Innovation Lagging? BioPlan Associates, Inc. January 2020 Introduction Although 2019 was overall a good year for biopharmaceutical product approvals, there was a lower percentage of approvals for fully new, innovative products compared with prior years. This may indicate problems with recent years’ pharmaceutical industry increased investment in biopharmaceutical vs. drug R&D, with a relative increase in resulting innovative product approvals not showing up yet. It may be too early to make conclusions regarding the extent of this pipeline trend, but the record portion of follow-on product approvals (63% of approvals) can be viewed as positive or negative for the industry. Biopharmaceuticals are here defined as prescription therapeutic products containing active agents manufactured using biotechnology methods, i.e., using living organisms (1). Figure 1 shows the numbers of recombinant and non-recombinant biopharmaceuticals approved by FDA since 1981, when the first recombinant protein received approval. Total biopharmaceutical approvals have increased over the years while remaining steady in the past few years. Figure 1: Numbers of Recombinant and Non-Recombinant Biopharmaceuticals Approved by FDA, 1981-2019 ©2020 BioPlan Associates, Inc, 2275 Research Blvd., Ste. 500, Rockville, MD 20850 (301) 921-5979 Page: 1 Confidential White Paper – Not for Distribution Approvals in 2019 In Table 1 we present approvals during 2019. Several oligonucleotide therapeutics, both antisense and RNAi, also received approval, but these are synthetically manufactured drugs and not considered biopharmaceuticals. Other products not included as biopharmaceuticals include medical devices, allergenic extract products, and diagnostics that receive biologics (BLA) approvals.
    [Show full text]
  • The Biopharmaceutical Industry Is Leading the Way in Developing
    The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19 The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza, as well as experience working with health authorities and regulators to find a fast-tracked approach to bringing safe and effective medicines to market for patients. Biopharmaceutical companies are committed to developing solutions to help diagnose, treat and prevent COVID-19. Sharing the novel COVID-19 virus sequence helped to galvanise the research community The rapid virus sequencing by the scientific community enabled researchers to characterize and begin to understand the new threat posed by COVID-19. Biopharmaceutical companies with potentially relevant knowhow were thereby enabled to get their scientists to check their R&D libraries for potential assets that could fight coronaviruses. “Open Access” data-sharing channels are the backbone to securing a response capacity and have proven their worth with influenza networks. This speedy sharing of the novel coronavirus pathogen sequence was instrumental in galvanising global collaboration with the private and public sector: a pre-requisite for timely development of vaccines and treatments. The Global Initiative on Sharing All Influenza Data or GISAID Initiative, an open access platform partly funded by the private sector, played a critical role in sharing the first genome sequences of the novel coronavirus and centralizing their collection.
    [Show full text]
  • Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level – Isbn-92-64-01403-9 ©Oecd 2006 10 – Executive Summary
    EXECUTIVE SUMMARY – 9 Executive Summary Innovation policies and sectoral innovation systems Biotechnology has become the driving force of radical changes in innovation processes in various sectors. This is best illustrated by the pharmaceutical industry where the traditional chemical paradigm of drug discovery and development is being replaced by a new biotechnological paradigm. This has important consequences for the structure and functioning of the biopharmaceutical innovation system: biotechnology firms and public sector research organisations are becoming key actors generating new knowledge, tools and substances for the pharmaceutical industry. Regulations, standards and intellectual property rights (IPR) schemes have to deal with new types of components, and, on the demand side, new solutions are emerging for as yet unmet needs. For this reason the biopharmaceutical sectoral innovation system was chosen as one of the pilot sectors of the OECD Case Studies in Innovation.1 Building on previous work on national innovation systems (NIS), the OECD Case Studies in Innovation are aimed at improving the understanding of the idiosyncratic properties of particular areas of technology and sectoral innovation systems, so that a consistent and transparent policy mix can be designed that combines generic innovation policies with customised policies adapted to the characteristics of a specific area of technology or of a sectoral innovation system. Aims of the case study The general aim of the case study on pharmaceutical biotechnology was to provide
    [Show full text]
  • Considerations for Applying Bioethics Norms to a Biopharmaceutical Industry Setting Luann E
    Van Campen et al. BMC Med Ethics (2021) 22:31 https://doi.org/10.1186/s12910-021-00600-y DEBATE Open Access Considerations for applying bioethics norms to a biopharmaceutical industry setting Luann E. Van Campen1,2* , Tatjana Poplazarova3, Donald G. Therasse2 and Michael Turik2,4 on behalf of The Biopharmaceutical Bioethics Working Group Abstract Background: The biopharmaceutical industry operates at the intersection of life sciences, clinical research, clini‑ cal care, public health, and business, which presents distinct operational and ethical challenges. This setting merits focused bioethics consideration to complement legal compliance and business ethics eforts. However, bioethics as applied to a biopharmaceutical industry setting often is construed either too broadly or too narrowly with little exami‑ nation of its proper scope. Main text: Any institution with a scientifc or healthcare mission should engage bioethics norms to navigate ethi‑ cal issues that arise from the conduct of biomedical research, delivery of clinical care, or implementation of public health programs. It is reasonable to assume that while bioethics norms must remain constant, their application will vary depending on the characteristics of a given setting. Context “specifcation” substantively refnes ethics norms for a particular discipline or setting and is an expected, needed and progressive ethical activity. In order for this activ‑ ity to be meaningful, the scope for bioethics application and the relevant contextual factors of the setting need to be delineated and appreciated. This paper defnes biopharmaceutical bioethics as: the application of bioethics norms (concepts, principles, and rules) to the research, development, supply, commercialization, and clinical use of biopharmaceuti- cal healthcare products.
    [Show full text]
  • A New Era in Biopharmaceutical Drug Development
    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.29.004753 A Systematic Review of Synthetic Biology - A New Era in Biopharmaceutical Drug Development Başak Kandemir1,2ϕ*, Oya Arı Uyar2ϴ*, E Damla Arısan1,3 and Işıl Aksan Kurnaz1,2* 1Gebze Technical University, Biotechnology Institute, 41400 Gebze, Kocaeli, Turkey 2BIOM Biotech LLC, TÜBİTAK Marmara Technokent, 41470, Gebze, Kocaeli, Turkey 3DAPGenomics LLC, Yıldız Teknik Technopark, Incubator, Istanbul-Turkey * Authors have contributed equally to this manuscript. ϕ Present address: Baskent University, Department of Molecular Biology and Genetics, Ankara ϴ Present address: TUBITAK Marmara Research Center (MAM), Gebze Kocaeli *Corresponding author: Işıl Aksan Kurnaz, Gebze Technical University, Institute of Biotechnology, Gebze Kocaeli Turkey ARTICLE INFO AbsTRACT Received: July 15, 2020 Although biotechnology dates back to ancient times, biotechnology as we know it started with the scientific advances elucidating fermentation, microorganisms, protein, Published: July 24, 2020 and DNA biochemistry. Today, modern biotechnology that uses recombinant DNA Citation: technology as its primary tool is undergoing transformation into synthetic biology. Nobel Prize in Chemistry 2018 was awarded in part to Prof. Frances Arnold, for her Başak Kandemir, Oya Arı Uyar, E work on enzyme evolution, who is also the founder of a synthetic biology company. Damla Arısan, Işıl Aksan Kurnaz. A System- Synthetic biology was first coined in 1990s and was initiated by engineers who have atic Review. of Synthetic Biology - A New dreamed of joining engineering principles with the concept of microbial cell factories, BJSTR.Era in MS.ID.004753.Biopharmaceutical Drug Develop- parallel to the genomic era and the birth of systems biology. It is built on the notion ment Biomed J Sci & Tech Res 29(1)-2020.
    [Show full text]
  • Ensuring U.S. Biopharmaceutical Competitiveness
    Ensuring U.S. Biopharmaceutical Competitiveness STEPHEN EZELL | JULY 2020 If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy. KEY TAKEAWAYS ▪ The biopharmaceutical industry makes important contributions to the U.S. economy, including employing over 500,000 workers making 1.4 times the U.S. earnings average. ▪ The United States leads the world on most indices of R&D investment and innovation. From 2004 to 2018, U.S.-headquartered firms produced almost twice as many new drugs as did firms in Europe, and 3 to 4 times as many as Japan. ▪ Despite U.S. strengths in biopharmaceutical R&D and innovation, manufacturing has dropped. From 2009 to 2018, real value-added output in pharmaceutical and medicines manufacturing fell by nearly one-third. ▪ Partly as a consequence, the U.S. trade balance in pharmaceuticals has grown from a deficit of $16 billion in 2010 to a deficit of $77 billion in 2019. ▪ Calls for reshoring more biopharmaceutical manufacturing should distinguish between mature manufacturing processes and those still evolving, as in continuous process biomanufacturing, where U.S.-based production can enjoy unique strengths. ▪ America must continually bolster its biopharmaceutical leadership position, especially as China implements ever-more aggressive policies to improve their life-sciences competitiveness, not only in production but also in innovation. ▪ To support the sector, policymakers should focus on: 1) maintaining strengths, including in pricing, tech transfer, and intellectual property; 2) spurring domestic innovation; 3) spurring increased domestic production; and 4) combatting foreign mercantilism.
    [Show full text]